In vitro activity of cefpirome and vancomycin in combination against gentamicin-susceptible and gentamicin-resistant Staphylococcus aureus

Carricajo, Anne; Vermesch, R.; Aubert, G.

doi:10.1046/j.1198-743x.2001.00238.x

Cited by 6 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 100 % susceptibility to GM observed in this study is in agreement with results obtained by Vignaroli et al (2013) who reported a 100 % susceptibility of E. coli isolates from coastal marine sediments to GM. The reemergence of GM-susceptible methicillin-resistant strains of Staphylococcus aureus (MRSA) has been shown in studies conducted in other countries (Sougakoff et al 1998;Blanc et al 2001;Carricajo et al 2001) as well as in South Africa (Essa et al 2009;Marais et al 2009;Heysell et al 2011;Moodley et al 2010). Similar GM susceptibility trends with E. coli observed in this study may indicate the possibility of genetic transfer within the aquatic environment.…”

Section: Prevalence Of Antibiotic-resistant E Coli In Water and Sedisupporting

confidence: 80%

High prevalence of multiple-antibiotic-resistant (MAR) Escherichia coli in river bed sediments of the Apies River, South Africa

Abia

Ubomba-Jaswa

Momba

2015

Environ Monit Assess

View full text Add to dashboard Cite

This study aimed at investigating the presence of antibiotic-resistant Escherichia coli in river bed sediments of the Apies River, Gauteng, South Africa, in order to better inform health management decisions designed to protect users of the river. Overall, 180 water and sediment samples were collected at 10 sites along the Apies River from January to February 2014. E. coli was enumerated using the Colilert® 18/Quanti-Tray® 2000 (IDEXX). Isolates were purified by streaking on eosin methylene blue agar followed by the indole test. Pure E. coli isolates were tested for resistance to nine antibiotics by the Kirby-Bauer disc diffusion method. Over 98% of the isolates were resistant to at least one of the antibiotics tested. The highest resistance was observed against nitrofurantoin (sediments) and ampicillin (water). Over 80% of all resistant isolates showed multiple antibiotic resistance (resistance to ≥3 antibiotics). The abundance of E. coli in the sediments not only adds to the evidence that sediments are a reservoir for bacteria and possibly other pathogens including antibiotic-resistant bacteria but also suggests that antibiotic-resistant genes could be transferred to pathogens due to the high prevalence of multiple-antibiotic-resistant (MAR) strains of E. coli observed in the sediment. Using untreated water from the Apies River following resuspension for drinking and other household purposes could pose serious health risks for users. Our results suggest that river bed sediments could serve as reservoirs for MAR bacteria including pathogens under different climatic conditions and their analysis could provide information of public health concerns.

show abstract

Section: Prevalence Of Antibiotic-resistant E Coli In Water and Sedisupporting

confidence: 80%

High prevalence of multiple-antibiotic-resistant (MAR) Escherichia coli in river bed sediments of the Apies River, South Africa

Abia

Ubomba-Jaswa

Momba

2015

Environ Monit Assess

View full text Add to dashboard Cite

show abstract

“…An in vitro pharmacodynamic study of vancomycin alone, cefazolin alone or in combination against MRSA was recently reported (Hagihara et al, 2012). The synergism of cefepime or cefpirome combined with vancomycin or teicoplanin against MRSA isolates has also been explored (Carricajo et al, 2001; Lozniewski et al, 2001; Toyokawa et al, 2003). Here, we conducted a comparative in vitro study of the combination of any of four generation cephalosporins with either vancomycin or teicoplanin against MRSA isolates by three laboratory methods to elucidate the variation in the antibacterial activity of different cephalosporin-glycopeptide (C-G) combinations.…”

Section: Introductionmentioning

confidence: 99%

Cephalosporin-Glycopeptide Combinations for Use against Clinical Methicillin-Resistant Staphylococcus aureus Isolates: Enhanced In vitro Antibacterial Activity

et al. 2017

View full text Add to dashboard Cite

The empirical combination of both a beta-lactam and glycopeptide to counter potential staphylococcal pathogens may improve the clinical outcomes for cases of Staphylococcus aureus bacteremia. We reported comparative in vitro studies of combination effects of different cephalosporins (i.e., cefazolin, cefmetazole, cefotaxime, and cefepime) combined with glycopeptides for 34 randomly selected methicillin-resistant S. aureus (MRSA) isolates by three methods, including the checkerboard, time-killing, and combination MIC measurement methods. Thirteen SCCmec type III isolates with a cefazolin MIC of ≥ 128 μg/mL were classified as the high-cefazolin MIC (HCM) group, whereas 13 SCCmec type IV and 8 SCCmec type V isolates were classified as the low-cefazolin MIC (LCM) group. With the checkerboard method, synergism was present for vancomycin-based combinations at 30.8–69.2 and 13.6–66.7%, as well as teicoplanin-based combinations of 38.5–84.6 and 0–47.6%, of the HCM and LCM isolates, respectively. No antagonism was noted. The in vitro inhibitory activity was evident even at a low concentration of 1/512x MIC of cephalosporin combined with sub-inhibitory concentrations (1/2x MIC) of a glycopeptide. With time-killing assays, synergism was noted at 1/2x or 1x susceptible breakpoint concentrations (SBCs) of a cephalosporin combined with 1/4 or 1/2 MIC of a glycopeptide. In the presence of 1/2 SBC of a cephalosporin, vancomycin or teicoplanin MICs decreased an average of 2.0- to 6.6- or 1.6- to 5.5-fold, respectively. With 8 μg/mL cephalosporin, the decline of glycopeptide MICs was most obvious in the presence of cefmetazole. In conclusion, cephalosporin-glycopeptide combinations at clinically achievable concentrations can exhibit in vitro synergistic antibacterial activity against clinical MRSA isolates. Such combinations require more clinical data to support their application for use in human MRSA infections.

show abstract

Vancomycin in Combination with Other Antibiotics for the Treatment of Serious Methicillin‐ResistantStaphylococcus aureusInfections

2009

View full text Add to dashboard Cite

Vancomycin is often combined with a second antibiotic, most often rifampin or gentamicin, for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Published data from experiments evaluating these and other vancomycin-based combinations, both in vitro and in animal models of infection, often yield inconsistent results, however. More importantly, no data are available from randomized clinical trials to support their use, and some regimens are known to have potential toxicities. Clinicians should carefully reconsider the use of vancomycin-based combination therapies for the treatment of infection due to methicillin-resistant S. aureus.

show abstract

In vitro activity of cefpirome and vancomycin in combination against gentamicin-susceptible and gentamicin-resistant Staphylococcus aureus

Cited by 6 publications

References 9 publications

High prevalence of multiple-antibiotic-resistant (MAR) Escherichia coli in river bed sediments of the Apies River, South Africa

High prevalence of multiple-antibiotic-resistant (MAR) Escherichia coli in river bed sediments of the Apies River, South Africa

Cephalosporin-Glycopeptide Combinations for Use against Clinical Methicillin-Resistant Staphylococcus aureus Isolates: Enhanced In vitro Antibacterial Activity

Vancomycin in Combination with Other Antibiotics for the Treatment of Serious Methicillin‐ResistantStaphylococcus aureusInfections

Contact Info

Product

Resources

About